Xoma - Xoma Ltd - Page 8

Any estimates on the HOD (high of day)?
I'm hoping $1.15 but that could be a stretch.

I doubt it. Would be lucky to get into the mid 90s IMO

good call. this is one pathetic stock...until the big news hits.

shot up!

Good news today.

BIG NEWS

http://finance.yahoo.com/q?s=XOMA

# XOMA to Repay Goldman Loan: BioBuzzat TheStreet.com(Mon 8:55am)

# XOMA Announces Plan to Fully Repay Goldman Sachs LoanGlobeNewswire(Mon 7:30am)

# InPlay: XOMA Limited trading halted - news pendingBriefing.com(Mon 7:28am)

# XOMA LTD /DE/ Files SEC form 8-K, Other EventsEDGAR Online(Mon 6:02am)


From sept 9th:

# Xoma to receive $6 million in Cephalon partnershipAP(Wed, Sep 9)
# UPDATE - Xoma, Cephalon unit in $6 mln antibody discovery dealat Reuters(Wed, Sep 9)
# XOMA Announces $6 Million Antibody Discovery Collaboration With Arana TherapeuticsGlobeNewswire(Wed, Sep 9)

.9275 PM

Part of it will be paid through the sale of common stock. Dilution!

The rally didn't last.

More news coming out yesterday after hours that could help the cause.

XOMA Announces $6 Million Antibody Discovery Collaboration
Monday 09/14/2009 5:15 PM ET - Investrend

Related Companies
Symbol Last %Chg
CEPH 58.78 0.00%
XOMA 0.87 0.00%

As of 12:00 AM ET 9/14/09
(Comment on this article at http://www.financialwire.net/2009/09...llaboration-2/)

September 14, 2009 (FinancialWire) -- XOMA Ltd. (NASDAQ: XOMA) and Arana Therapeutics Ltd., a wholly-owned subsidiary of Cephalon, Inc. (NASDAQ: CEPH), have entered into a collaboration involving multiple proprietary XOMA antibody research and development technologies, including a new antibody phage display library, and a suite of integrated information and data management systems.

Arana has agreed to pay XOMA a fee of $6 million and XOMA will be entitled to milestone payments and royalties on product sales. Under the terms of the collaboration, XOMA will be fully reimbursed for all services it may provide to Arana under the agreement.

XOMA has developed integrated capabilities in antibody discovery, engineering and manufacturing, including maintaining the largest collection of commercially available antibody phage display libraries. The company also has expertise in the construction of large, novel and diverse libraries for screening and optimization that enable the selection of antibodies with very specific binding, affinity and potency characteristics to an antigen of choice.

The new, proprietary antibody library covered by the agreement with Arana, recently validated by XOMA, is one of a series of proprietary antibody libraries being developed by XOMA scientists to overcome existing limitations in library design by combining "best-in-class" techniques with XOMA's own proprietary and patent-protected technologies. Access to multiple libraries may offer a number of benefits to XOMA and its partners because it enables the use of libraries best suited to the needs of a particular discovery project. This increases the probability of technical and business success in finding rare and unique functional antibodies directed to targets of interest.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

http://www.financialwire.net

News

http://finance.yahoo.com/news/XOMA-t....html?x=0&.v=1

whadda think that does for the pps tomorrow?

I took this opportunity to dump my shares. I said if it got back up to $1 I would sell at 10% loss. This stock is a drag. I would not expect anything good for tomorrow. I may buy back when it gets back around .80.

Noticed that there are more buys on the L2 then sells..there has been dilution on this in the past so waiting to see how it plays out AH and PM..this stock has never closed above $1 which it did today and the volume today is the most it has ever had.

I think it will be up in the am but not for long.

You got that right, I missed the bottom call and bought 10k @ $0.94. Hoping for a pop. Looks lik $0.88/$0.89 is the bottom for this morning.

.86 IMO is pretty good entrance.

XOMA Completes Full Repayment of Goldman Sachs Loan

BERKELEY, Calif., Sep 24, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA) today announced that it has fully repaid its loan from Goldman Sachs Specialty Holdings, Inc. Repayment of the loan discharged all of XOMA's obligations to the lenders. The repayment resolves the uncertainty about the loan that arose from the sudden and unexpected withdrawal of RAPTIVA(R) from the market earlier this year, which triggered XOMA to begin to renegotiate the loan that was secured by royalties from RAPTIVA(R), LUCENTIS(R) and CIMZIA(R).
"We are pleased to have successfully concluded this matter. We have strengthened our financial condition by removing a burden on our balance sheet, eliminating interest costs and improving XOMA's freedom to operate," said Steven B. Engle, XOMA's Chairman and Chief Executive Officer. "Using the LUCENTIS(R) royalty buyout payment to help fund the loan repayment is non-dilutive to shareholders and removes potential uncertainties related to LUCENTIS's(R) future. Eliminating the loan overhang will also strengthen our position in negotiating future collaborations, including our antibody technology collaborations and a corporate partnership for XOMA 052."
XOMA repaid the entire $44.3 million in principal and interest on the loan with proceeds from: a $25 million buyout by Genentech of XOMA's royalty interest in LUCENTIS(R); an equity offering of $12.3 million; the restricted cash account reserved for loan repayment containing $6.1 million; and $0.9 million from XOMA's cash reserves. In addition, XOMA was required to pay a prepayment penalty of 6% of the loan balance, or $2.5 million, from its cash reserves.
"Based on estimated revenues and expenses and without including an anticipated corporate partnership for XOMA 052, we estimate our cash resources after full payment of the loan are sufficient to fund operations into the first quarter of 2010," said Fred Kurland, XOMA's Vice President, Finance and Chief Financial Officer. "As a result of the loan repayment, we have eliminated future interest charges that would have totaled $5.1 million in 2009, freed up the future flow of royalty income from CIMZIA(R) sales for use in funding company operations and avoided restructuring costs and future loan constraints."
XOMA receives royalties from UCB, S.A. based on U.S. and Swiss sales of CIMZIA(R), which is being launched in the U.S. for the treatment of rheumatoid arthritis and is approved for treatment of Crohn's disease.
About XOMA
XOMA discovers, develops and manufactures therapeutic antibodies designed to treat inflammatory, autoimmune, infectious and oncological diseases. The Company's proprietary product pipeline includes XOMA 052, an anti-IL-1 beta antibody, and XOMA 3AB, a biodefense anti-botulism antibody candidate.
XOMA has multiple revenue streams resulting from the licensing of its antibody technologies, product royalties, development collaborations, and biodefense contracts. XOMA's technologies have contributed to the success of marketed antibody products, including LUCENTIS(R) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(R) (certolizumab pegol) for rheumatoid arthritis and Crohn's disease.
The company has a premier antibody discovery and development platform that incorporates leading, unmatched capabilities in antibody phage display and a unique collection of antibody display libraries, as well as XOMA's proprietary Targeted Affinity Enhancement technology for antibody humanization and bacterial cell expression and manufacturing technologies. Bacterial cell expression is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. As a result, more than 50 pharmaceutical and biotechnology companies have signed BCE licenses. XOMA recently signed a $6 million agreement with Arana Therapeutics subsidiary of Cephalon, Inc. (Nasdaq:CEPH) for a collaboration involving multiple proprietary XOMA antibody research and development technologies, including a new antibody phage display library, and a suite of integrated information and data management systems.

Will the above post have any effect on the stock?
I wish it would but I doubt it.

It should, but I believe some are being turned off to the issuing of shares. I would at least like to get a pop to my purchase price. At least we know it is safe through the 1st quarter.

i bought in at .86 and its down. Cut my losses? or hold for a lil longer?

I cut half and got into RZ, still sitting on 5k shares - this will swing to near $1 in time. I know several folks that trade it often, I just missed the buy.